Heat Biologics Inc (HTBX.OQ)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|54||2008||Chairman of the Board, Chief Executive Officer|
|59||2017||Chief Operating Officer, Chief Scientific Officer|
|64||2016||Vice President - Finance, Controller, Corporate Secretary|
|64||2017||Independent Lead Director|
- BRIEF-Heat Biologics Files For Offering Of Up To $15 Mln Of Its Common Stock
- BRIEF-Heat Biologics Reports Data From Phase 2 Trial Of HS-410 Combined With Bacillus Calmette-Guérin For Treating Non-Muscle Invasive Bladder Cancer
- BRIEF-Heat Biologics Files Prospectus Supplement Related To Offering Of Up To $1.3 Million Shares Of Co's Common Stock
- BRIEF-Heat Biologics - Interim Results From Phase 2 Study Investigating HS-110 In Combination With Anti-PD-1
- BRIEF-Heat Biologics Gets Recommendation To Continue Patient Enrollment Of Ongoing Phase 2 Clinical Trial